Drug intelligence / Profile preview

ETN103

Development stage: Preclinical
Lead developer: Etnova Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ETN103 is a preclinical-stage therapeutic candidate being developed by Etnova Therapeutics for the treatment of neurodegenerative brain diseases, specifically dementia. The drug's mechanism of action involves the induction of neuronal proliferation and differentiation, aiming to promote neuro-regeneration in the brain. As of 2024, the program is undergoing mechanism of action (MOA) verification and efficacy testing in animal models. Etnova Therapeutics focuses on small molecule-based neuro-regeneration, and ETN103 is part of their pipeline targeting cognitive decline and brain degeneration.

Beyond the preview

Go deeper on ETN103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ETN103.

Explore the full profile